Portfolio Snapshots

We are an international equities manager, and we invest with a truly global outlook.

Here is a snapshot of the current portfolio disposition of our flagship Platinum Trust Funds and their key holdings.

Platinum International Health Care Fund

Platinum International Health Care Fund invests in health care companies from around the world, ranging from those engaged in early exploratory research to those providing health care services directly to consumers.

Established in 2003, the fund now has A$328.0 million under management^ and a track record of achieving 10.7% compound return annually since inception (on 10/11/2003).*

Platinum International Health Care Fund provides exposure to companies engaged in the provision of a wide range of products and services within the global healthcare ecosystem. It invests in multinational pharmaceuticals as well as emerging biotechs with cutting-edge R&D; hospital chains and nursing care operators as well as providers of diagnostic and laboratory technologies; health insurers as well as healthcare software providers.

Industry Breakdown1
SectorLong % Short %Net %
Health Care 91.2 (3.4) 87.7
Top 10 Positions3
StockCountryIndustry%
SpeeDx Pty Ltd Australia Biotechnology 5.2
Takeda Pharma Co Japan Pharmaceuticals 4.2
Sanofi SA France Pharmaceuticals 3.5
BioNTech Germany Biotechnology 3.3
Quanterix Corp United States Life Sciences Tools & Services 2.4
UCB SA Belgium Pharmaceuticals 2.4
Gilead Sciences Inc United States Biotechnology 2.3
Roche Holding AG Switzerland Pharmaceuticals 2.1
Zai Lab Ltd ADR China Biotechnology 2.0
Telix Pharmaceutical Australia Biotechnology 2.0
Total 29.5
Disposition of Assets2
Long %Short %Net %Currency%
Asia-Pacific 24.9 (0.9) 24.0 20.7
Australia 11.3 (0.6) 10.7 9.8
China Ex PRC 5.3 - 5.3 -
Hong Kong 1.1 - 1.1 3.9
Japan 6.8 (0.3) 6.5 7.0
Singapore 0.3 - 0.3 -
Europe 27.7 (0.6) 27.1 29.3
Belgium 2.4 - 2.4 -
Denmark 1.6 - 1.6 1.6
France 4.5 - 4.5 -
Germany 6.9 (0.3) 6.6 -
Ireland 0.8 - 0.8 -
Italy - (0.3) (0.3) -
Netherlands 1.8 - 1.8 -
Spain 1.9 - 1.9 -
Sweden 1.5 - 1.5 1.5
Switzerland 2.8 - 2.8 3.3
United Kingdom 3.6 - 3.6 2.2
Euro - - - 20.8
North America 38.6 (2.0) 36.7 50.0
Canada 0.9 - 0.9 -
United States 37.7 (2.0) 35.8 50.0
Sub-Total 91.2 (3.4) 87.7 100.0
Cash 8.8 - 12.3 -
Total 100.0 - 100.0 100.0
Long - 74 stocks, 2 options Short - 5 swaps
Top 10 Positions3
StockCountryIndustry%
SpeeDx Pty Ltd Australia Biotechnology 5.2
Takeda Pharma Co Japan Pharmaceuticals 4.2
Sanofi SA France Pharmaceuticals 3.5
BioNTech Germany Biotechnology 3.3
Quanterix Corp United States Life Sciences Tools & Services 2.4
UCB SA Belgium Pharmaceuticals 2.4
Gilead Sciences Inc United States Biotechnology 2.3
Roche Holding AG Switzerland Pharmaceuticals 2.1
Zai Lab Ltd ADR China Biotechnology 2.0
Telix Pharmaceutical Australia Biotechnology 2.0
Total 29.5
All data as at [30 April 2020] .
  1. “Long %” represents the Fund’s effective exposures to the relevant sectors as a percentage of the Fund’s NAV, taking into account direct stock holdings and long derivative positions (stocks and indices). “Net %” represents the Fund’s net exposures to the relevant sectors as a percentage of the Fund’s NAV, taking into account direct stock holdings and both long and short derivative positions (stocks and indices).
  2. “Long %” represents the Fund’s effective exposures to the relevant regions as a percentage of NAV through stock holdings and long derivatives (stocks and indices). “Net %” represents the Fund’s net exposures to the relevant regions as a percentage of NAV through stock holdings and both long and short derivatives (stocks and indices). “Currency %” represents the Fund’s effective exposures to the relevant currencies as a percentage of NAV through stock holdings, cash and the use of derivatives.
  3. The “Top 10 Positions” table shows the Fund’s top 10 long stock positions as a percentage of the Fund's NAV, taking into account direct stock holdings and long derivative positions.